ASO VISUAL ABSTRACT




## ASO Visual Abstract: PET Imaging and Rate of Pathologic Complete Response in Esophageal Squamous Cell Carcinoma

M. Hart Squires, MD<sup>1</sup>, Nicole Gower, BS<sup>1</sup>, Jennifer H. Benbow, PhD<sup>1</sup>, Erin E. Donahue, PhD<sup>1</sup>, Casey E. Bohl, MD, PhD<sup>2</sup>, Roshan S. Prabhu, MD<sup>3</sup>, Joshua S. Hill, MS, MD<sup>1</sup>, and Jonathan C. Salo, MD, FACS<sup>1</sup>

<sup>1</sup>Levine Cancer Institute, Atrium Health, Charlotte, NC; <sup>2</sup>Atrium Health, Charlotte, NC; <sup>3</sup>Southeast Radiation Oncology Group, Carolinas Medical Center, Levine Cancer Institute, Atrium Health, Charlotte, NC

For patients with esophageal squamous cell carcinoma with a clinical response to chemoradiation, a strategy of active surveillance has been proposed. We show that positron emission tomography (PET) is a poor predictor of who will experience a pathologic complete response to chemoradiation (https://doi.org/10.1245/s10434-021-1064 4-4).

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© Society of Surgical Oncology 2021

Published Online: 21 September 2021

J. C. Salo, MD, FACS e-mail: Jonathan.salo@atriumhealth.org